CAMBRIDGE

Cambridge University Press
978-0-521-17513-5 - Nitric Oxide in Bone and Joint Disease
Mika V. J. Hukkanen, Julia M. Polak and Sean P. F. Hughes
Index
More information

Index

acetylcholine
  bone blood flow response 132, 133, 136, 137
  synovial blood flow response 47–9
achondroplasia 30
acid phosphatase 122, 123
acro-osteolysis 82
activator protein 1 (AP-1) 10, 11, 89
adjuvant-induced arthritis 16, 63
  NOS inhibitors 64, 65–6, 72
  selective COX-2 inhibitors 73
  synovial blood flow 48–9
alkaline phosphatase 109
alveolitis, pulmonary 15
aminoguanidine 12
  allograft survival and 14
  bone metabolism and 119
  in experimental arthritis 64, 66
  in experimental diabetes 15
  in experimental inflammation 75
angiotensin II 43
animal models of arthritis, *see* experimental models of arthritis
apoptosis
  articular chondrocytes 98
  osteoblasts 110
  osteoclast progenitors 118
L-arginine 3, 4, 11
  effects on lymphocytes 12
  synovial blood flow and 47, 48
argininosuccinate synthetase 11
arthritis
  infective 81
  inflammatory, *see* inflammatory arthritis
  see also osteoarthritis; rheumatoid arthritis
aseptic loosening of hip prostheses, *see* hip prostheses, aseptic loosening
athletes 141
ATP production 98
autoimmune diseases 15, 53

blood flow
  bone, *see* bone blood flow
  synovial joint 41–50
bone
  allograft preservation 137
  biology 21–37
  disease, role of NO 119–20
  erosions in rheumatoid arthritis, *see* rheumatoid arthritis, bone erosions/synovitis
  fluid flow, *see* fluid flow, in bone
  growth 22
  matrix proteins 22
  organ cultures, mechanical loading 154–6
  vascular anatomy 129–30, 131
bone blood flow 129–39
  adrenergic control 130–2
  anatomical basis 129–30, 131
  endothelial-dependent control 132–3
  mechanical influences 163
  pathophysiology 136–8
  role in bone physiology 133–5, 141–2
bone cells
  cultured, mechanical responses 156–8, 174, 175–6
  cytokine production 25
  differentiation and function 22–7
  effects of NO 117–19
  fluid flow responses 157, 175–6
  ion channels 163
  mechanical strain responses 154–64, 169–76
  NOS expression 116–17, 144, 154, 161–2
  NOS inhibition *in vivo* 162–3
  see also osteoblasts; osteoclasts; osteocytes
bone formation 23, 105
  effects of NO 118
  mechanical strain inducing 152, 158, 169, 170–6
  venous pressure and 134–5
  see also bone resorption
bone marrow stromal cells 25, 26, 116
bone metabolism 21–2
  effects of NO 119
  regulation in health and disease 34–6
  regulatory factors 24, 27–33
  role of microcirculation 133–4
bone morphogenetic proteins (BMPs) 23, 25, 32, 85

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-17513-5 - Nitric Oxide in Bone and Joint Disease
Mika V. J. Hukkanen, Julia M. Polak and Sean P. F. Hughes
Index
More information

bone remodelling 21, 22, 27, 84
  fluid flow-mediated 143–4, 146
  mechanically induced 151–2
  see also bone formation; bone resorption
bone resorption 23, 105
  around hip prostheses 178–82
  factors affecting 24, 84–7
  linking (coupling) to formation 25–7, 105
  mechanical strain effects 151–2
  oestrogen lack and 137
  phase 122, 124
  reactive oxygen species and 85, 86–7, 90–1, 92
  role of NO 92, 117–18, 123–5
  uncoupling from formation 93
Borrelia burgdorferi, murine 63, 64
brachypodism 32
bradykinin 85

calcitonin 85, 123–4, 146
calcitonin gene-related peptide (CGRP) 44–5, 82, 130
  in fracture healing 138
calcium
  concentration, NOS activity and 8, 11
  intracellular, in osteoclasts 122, 123–4
  metabolism, regulation 21
calcium channels, voltage-gated 163
calmodulin 3, 8
capillaries
  in bone 130
  pressure, bone formation and 134–5
carrageenan injection models
  knee joint 44, 47–8
  rat paw 71, 72–3, 74–5
  rat subcutaneous air pouch 72, 75
cartilage
  matrix, effects of NO 65, 96–7
  NO production 61–3, 95–6
    in arthritis 98–9
  regulatory factors 24, 27–33
  see also chondrocytes
cartilage-derived morphogenetic proteins (CDMPs) 23, 32
chondrocytes
  effects of NO 97–8
  NO and COX interactions 45
  NO synthesis 42, 95–6
    in arthritis 55, 61–3
  see also cartilage
L-citrulline 3, 4
cNOS, *see* constitutive nitric oxide synthase
collagen-induced arthritis 53, 63
  NOS inhibitors 64, 66
collagen synthesis 97, 170–1
collagenase (MMP-1) 27, 89
colony-stimulating factors (CSFs) 23, 24, 25, 28–9
  bone resorption and 85, 86
complement, NO interaction 15
constitutive nitric oxide synthase (cNOS) 8, 107
  in bone cells 144, 154, 161–2, 182
  in experimental inflammation 71
  in immune responses 9
  mechanical stimuli activating 158, 173
  see also endothelial nitric oxide synthase (eNOS); neuronal nitric oxide synthase (nNOS)
corticosteroids, *see* glucocorticoids
COX, *see* cyclooxygenase
cyclic AMP (cAMP), fluid shear stress and 144
cyclic GMP (cGMP) 5, 41
cyclooxygenase (COX) 70
  constitutive isoform (COX-1) 70
    activation by NO 75, 76–7
  hypoxia-mediated induction 88
  inducible isoform (COX-2) 33, 70–1
    activation by NO 73–5, 76, 77, 111–12
    in experimental inflammation 72–3, 74–5
    inhibition of induction by NO 97–8
    loosening of hip prostheses and 181–2
    mechanical stimuli inducing 172
    selective inhibitors, *see* non-steroidal anti-inflammatory drugs (NSAIDs), COX-2-selective
  NO interactions 71, 73–7, 111–12
  synovial blood flow and 45
cytochrome *c* oxidase 5
cytochrome P450 reductase 3, 8
cytokines 5
  actions on bone cells 107, 108, 117
  bone formation and 23
  bone resorption and 23, 84–6, 92
  gene polymorphisms 34
  hypoxia-mediated release 88
  iNOS activation 9, 11
  in loosening of hip prostheses 180
  NO effects on production 13
  NO as mediator of effects 116–20
  oestrogen interactions 35–6
  production by bone cells 25
  receptors 34
  regulating bone and cartilage 24, 27–33
  in rheumatoid arthritis 58
  systemic *vs* local effects 34–5
  see also specific cytokines

dexamethasone 72, 76
dextran-induced oedema in rat skin/paw 71
diabetes mellitus, insulin-dependent (IDDM) 15
1,25-dihydroxy vitamin D 25, 84, 85, 117
diphenylene iodonium chloride (DPI) 64

eicosanoids 33
electrokinetic migration 144
endothelial cells
  fluid flow responses 146, 158–9
  ion channels 163
  in ischaemia/reperfusion injury 136, 137
  oestrogen receptors 137
  prostaglandin release 152–3
  in rheumatoid arthritis 88
  synovial, NO production 63
endothelial nitric oxide synthase (eNOS) 3, 4, 8
  in bone cells 108, 116–17, 161–2, 164
  in bone–hip implant interaction 182

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-17513-5 - Nitric Oxide in Bone and Joint Disease
Mika V. J. Hukkanen, Julia M. Polak and Sean P. F. Hughes
Index
More information

expression 4–5
in fracture healing 138
in inflammation 70
knock-out mice 164
in osteoclastic bone resorption 122, 124
regulation of activity 11
endothelial permeability 12, 71
endothelin-1 58
endothelium-derived relaxing factor (EDRF) 8, 12, 41
endotoxin, *see* lipopolysaccharide
eNOS, *see* endothelial nitric oxide synthase
epidermal growth factor 85
experimental allergic encephalomyelitis (EAE) 15, 53
experimental models of arthritis 16, 53, 61–7, 119
NO production 61–5, 72
NOS inhibitors 64, 65–7, 72
role of NO in pathophysiology 65
synovial blood flow 44, 47–9

fibroblast growth factors (FGF) 23, 25, 30, 85
fibroblasts
COX-2/NO interactions 74
synovial
NO synthesis 42, 56, 63
in rheumatoid arthritis 87–8
fibronectin, chondrocyte interactions 98
fluid flow
in bone 142–3, 174
hormonal control 145–6
bone cell responses 157, 175–6
bone remodelling and 143–4
shear stress induced by, *see* shear stress, fluid flow-induced
vs mechanical strain 147, 175–6
c-*fos* 89, 146
activation by NO 173
mechanically induced expression 170, 171–2
fracture repair 134, 138, 141–2

G proteins 145
giant cells, foreign body 179
glucocorticoids 85
in experimental inflammation 72, 76
hip prosthesis loosening and 182
regulation of iNOS 11
in rheumatoid arthritis 66, 82
glucose 6-phosphate dehydrogenase (G6PD) 152–3, 159–60, 162–3, 173
gout 55
graft rejection 14–15
graft versus host disease (GVHD) 15–16
granulocyte-macrophage colony-stimulating factor (GM-CSF) 28–9, 36, 85, 86
granulomas, foreign body 179
growth factors
receptors 34
regulating bone and cartilage 24, 25, 27–33, 85
GTP cyclohydroxylase I 11
guanylyl cyclase 4, 5, 111

haem 3–4, 5
haemoglobin 6
Haversian canals 130
head-down tilt 142, 156–7
hemiplegia 82
heparin 85
hip prostheses, aseptic loosening 178–82
cytokines and NO mediating 180
future developments 182
iNOS and COX-2 181–2
proposed model 182
pseudomembrane formation 179
wear debris and 179–80
Howship's lacunae 90
hydrochloric acid 122, 123
hydrogen peroxide 91, 92, 180
hydronephrosis, experimental 72, 75
15-hydroperoxyeicosatetraenoic acid 159
hydroxyl radical 74, 93
hypercalcaemia of malignancy 32
hypoxia
in rheumatoid joints 87
role in rheumatoid erosions 83, 87–91
xanthine oxidoreductase upregulation 92
hypoxia-inducible factor (HIF) 88, 92
hypoxia-response elements 10, 88, 89

IFN-γ, *see* interferon-γ
IFN-γ-related transcription factor-1 (IRF-1) 10
IGFs, *see* insulin-like growth factors
immune-complex-mediated disease 15–16
immune responses 8–16, 65
in vivo, NO and 13–16
NOS regulation during 9–12
indomethacin 76
in experimental arthritis 66
hip prosthesis loosening and 182
mechanical strain and 152, 159, 172, 173
inducible nitric oxide synthase (iNOS) 3–4, 107
activating factors 9
in acute and chronic inflammation 70, 71
in bone cells 107, 116–17, 154, 161–2
cells expressing 5, 8–9
in chondrocytes 96
constitutive expression 5, 10
in experimental arthritis 72
in experimental inflammation 71, 74–5
in fracture healing 138
gene promoter/enhancer sites 10–11, 89
in human arthritides 55–6, 57, 62, 99, 109
inhibitory agents 10
knockout mice 14, 65, 72
loosening of hip prostheses and 180, 181–2
mRNA stability 11
post-translational regulation 11
regulation of expression 9–12
in rheumatoid arthritis 54, 89, 92, 119
selective inhibition 76, 182
in synovial joints 42
infections, immune responses to 13–14
infective arthritis 81
inflammation
NO and prostaglandin interactions 70–7

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-17513-5 - Nitric Oxide in Bone and Joint Disease
Mika V. J. Hukkanen, Julia M. Polak and Sean P. F. Hughes
Index
More information

inflammation (cont.)
  NOS regulation during 9–10
  role of NO 12, 65
inflammatory arthritis 41–50
  experimental models, *see* experimental models of arthritis
  human, NO production 53–8, 61, 62, 71–2, 109
  role of NO in pathophysiology 65
  see also osteoarthritis; rheumatoid arthritis
inflammatory bowel disease (IBD) 15–16
iNOS, *see* inducible nitric oxide synthase
insulin like growth factor I (IGF-I) 23, 30
  gene, mechanically induced expression 170–3
insulin-like growth factor II (IGF-II) 23, 30, 160
insulin-like growth factors (IGFs) 25, 30, 85
integrins, in rheumatoid arthritis 88
interferon-γ (IFN-γ)
  actions on bone/cartilage 29–30, 86
  actions on osteoblasts 108, 109
  iNOS induction 9, 10
  NO effects on production 13
  regulation of iNOS expression 10, 11
interleukin 1 (IL-1)
  actions on bone/cartilage 27, 29, 85, 86, 118
  actions on osteoblasts 108, 109, 110
  β (IL-1β), iNOS regulation 9, 11
  chondrocyte responses 95, 96
  IL-6 induction 28
  in loosening of hip prostheses 180
  oestrogens and 35, 36
  in rheumatoid erosions 88–9, 92, 119
interleukin 1 receptor antagonist (IL-1 ra) 27–8
interleukin 2 (IL-2) 86
interleukin 3 (IL-3) 86
interleukin 4 (IL-4) 10, 11, 86
  NO effects on production 13
interleukin 6 (IL-6) 23, 25
  actions on bone and cartilage 28, 85, 86
  effects of NO on production 97, 118
  oestrogens and 36, 137
interleukin 8 (IL-8) 86
interleukin 10 (IL-10) 10, 88
interleukin 11 (IL-11) 23, 25, 85, 86
interleukin 12 (IL-12) 16
intraosseous vascular pressure 130, 141–2
ion channels, bone cells 163
ischaemia/reperfusion injury
in bone 136–7
in rheumatoid joints 87

joints, synovial
  blood flow 41–50
    effects of inflammation 47–9
    regulation 42–5
  sites of NO synthesis 42, 43, 61–3
  sympathetic-mediated vasoconstriction 45–6, 47
c-*jun* 89

lactic acid 98
LAP (latency associated protein) 32
laser Doppler perfusion imaging 47, 48
Leishmania major infections 13, 14
leukocytes, synovial, NO production 42, 63
leukotrienes 33
lipopolysaccharide (LPS, endotoxin) 5, 9, 14
  actions on osteoblasts 108
  COX-2 induction 73
  IL-6 induction 28
  iNOS induction 73
locomotion
  fluid shear stress 146
  mechanical strain effects 151
long-term potentiation/depression 153–4, 164
Lyme disease, murine 63, 64
lymphocytes 88
  see also T lymphocytes

macrophage colony-stimulating factor (M-CSF) 29, 85, 86
macrophages
  COX-2/NO interactions 73
  cytokine production 13
  iNOS expression 8, 9
  loosening of hip prostheses and 179, 180, 181
  NO-dependent activity 13–14
  regulation of iNOS expression 10
  in rheumatoid arthritis 88
matrix metalloproteinases (MMPs) 27, 97, 119
mechanical strain 34, 151–64, 169–76
  adaptive bone responses 141, 151–2, 169
  cultured bone cells 156–8, 174, 175–6
  fluid flow induced by 143, 174
  hip prosthesis-associated 181–2
  NO production induced by 135, 154–64, 173
    bone cells responsible for 160–3
    by non-load-bearing bones 160
    prostaglandin production and 159–60, 173
  NOS expression and 108, 161–2
  prostaglandin production and 152–3, 159–60, 172–3, 174
  rat tail vertebra model 170
  vs fluid flow 147, 175–6
mechanotransduction 145, 152, 170–3
M-CSF, *see* macrophage colony-stimulating factor
memory, strain 153–4, 157, 164
metalloproteinases, matrix (MMPs) 27, 97, 119
metaphyseal dysplasia, Jansen type 33
methylene blue 74
MMPs, *see* matrix metalloproteinases
mononuclear cells, peripheral blood
  cytokine production 13
  NO production, in arthritis 54, 63
MRL-*lpr/lpr* mice 16, 53, 63, 72
  NOS inhibitors 64
c-*myc* 89

NADPH 3, 173
L-NAME (L-N^{ω}-nitro-L-arginine methylester)
  in experimental arthritis 64, 66
  in experimental bone ischaemia 136
  in experimental inflammation 71
  in vivo effects on bone cells 162
  mechanical loading responses and 173

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-17513-5 - Nitric Oxide in Bone and Joint Disease
Mika V. J. Hukkanen, Julia M. Polak and Sean P. F. Hughes
Index
More information

synovial blood flow and 43–4, 46, 47, 48
natural killer (NK) cells 12, 14
nerves
in fracture healing 138
perivascular, in bone 130
rheumatoid erosions and 82
synovial, NO production 46
neuronal nitric oxide synthase (nNOS) 3, 4, 8
in bone cells 108, 116, 117, 144, 161–2
expression 4–5
novel form, in osteoarthritic joints (OA-NOS) 9, 63, 96
regulation of activity 11
in synovial joints 42, 46
neuropeptides 24, 82, 130
neutrophils 12, 88
NF-IL6 10
NF-κB 10–11, 89, 97
L-NIL (*N*-iminoethyl-L-lysine) 12
in experimental arthritis 64, 66, 72
in experimental inflammation 71, 74–5
nitrate:creatinine ratio, urinary 54
nitrate, urinary, in arthritis 54, 72
nitric oxide (NO)
synthesis, *see* synthesis of NO
targets 5
transport 6
nitric oxide (NO) metabolites
serum, in arthritis 41, 54, 62
synovial fluid, in arthritis 41, 55, 62
urinary, in arthritis 54, 62, 72
nitric oxide synthase (NOS) 3
in bone cells 116, 144, 154, 161–2
constitutive isoforms (cNOS), *see* constitutive nitric oxide synthase
endothelial isoform (eNOS), *see* endothelial nitric oxide synthase
inducible isoform (iNOS), *see* inducible nitric oxide synthase
isoforms 3, 4–5, 8–9, 107
neuronal isoform (nNOS), *see* neuronal nitric oxide synthase
novel form, in osteoarthritic joints (OA-NOS) 9, 63, 96
in osteoblasts 108–9, 116–17
regulation in immune responses 9–12
nitric oxide synthase (NOS) inhibitors 11–12
actions on osteoblasts 108, 109, 112
adverse effects of non-selective 75, 76
in experimental arthritis 64, 65–7, 72
in experimental inflammation 71, 72
in vivo effects on bone cells 162–3
isoform-specific 11–12, 76, 182
mechanical loading responses and 155, 173
prostaglandin release inhibition 73, 74–5
therapeutic potential 67
nitrite
production
in arthritis 55
osteoblasts 106, 107–8
serum, in arthritis 54, 72
synovial fluid, in arthritis 55, 61, 72
nitrogen species, reactive
bone resorption and 85, 86–7, 92–3
see also peroxynitrite
S-nitroso-acetylpenicillamine (SNAP) 56, 112
nitrosoglutathione 6, 57
nitrosothiols 6
3-nitrotyrosine
loosening of hip prostheses and 181
serum, in arthritis 54, 72
synovial fluid, in arthritis 55, 72
L-NMMA (L-N^{ω}-methylarginine) 11–12
in experimental arthritis 53, 64, 66, 72
in experimental inflammation 71
in vivo effects on bone cells 162
mechanical loading responses and 159, 173
synovial blood flow and 46
L-NNA (L-N^{ω}-nitroarginine) 11–12, 112
nNOS, *see* neuronal nitric oxide synthase
non-obese diabetic (NOD) mouse 15, 53
non-steroidal anti-inflammatory drugs (NSAIDs) 33
COX-2-selective
in experimental arthritis 73
in experimental inflammation 72, 73
hip prosthesis loosening and 182
in experimental inflammation 72–3
in rheumatoid arthritis 83, 88
noradrenaline
bone blood flow and 130–2, 133
synovial blood flow and 45–6, 47
NOS, *see* nitric oxide synthase
nutrient artery 129

oedema, inflammatory 71
oestradiol 137
actions on osteoclasts 123–4
oestrogens
cytokine interactions 35–6
receptors in bone 35, 137
oophorectomy 125, 137
op/op mouse 29
orthopaedic implant failure 141, 178–82
osteoarthritis (OA) 81
excessive NO production 54, 55, 62, 72, 98–9
novel form of NOS (OA-NOS) 9, 63, 96
synovial iNOS expression 56, 57
osteoblasts 21, 84, 105–12
cytokine production 25
differentiation 23, 29
effects of NO 109–10, 118
factors affecting 31
fluid flow effects 143, 144–6, 147, 157–8, 175–6
function 22, 23
in vivo effects of NOS inhibitors 162–3
ion channels 163
load-related NO production 159–60, 161
load-related prostaglandin production 159–60
in loosening of hip prostheses 180, 181–2
mechanisms of NO actions 110–12
NO production 106, 107–10
NOS expression 108–9, 116–17, 162
osteoclast interactions 25–7, 91
osteocalcin 109, 170–1

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-17513-5 - Nitric Oxide in Bone and Joint Disease
Mika V. J. Hukkanen, Julia M. Polak and Sean P. F. Hughes
Index
More information

osteoclast-activating factors (OAFs) 27
osteoclasts 21, 84, 122–5
  cyclic activity 122, 124
  differentiation 23, 25, 26, 29, 118
  effects of NO 117–18, 123–4
  fluid flow effects 143–4
  function 22, 23, 26
  in loosening of hip prostheses 180
  mechanisms of bone resorption 90, 91
  NOS expression 116, 117
  osteoblast interactions 25–7, 91
  see also bone resorption
osteocytes
  fluid flow effects 143, 157–8, 175–6
  in vivo effects of NOS inhibitors 162–3
  ion channels 163
  NOS expression 116, 162
  responses to mechanical loading 169, 175–6, 181
    induced gene expression 170–2
    NO production 159–60, 161, 164, 173
    prostaglandin production 159–60, 172–3
osteogenesis, *see* bone formation
osteopontin 89, 147
osteoporosis
  disuse 141
  pathogenesis 22, 35–6, 137
  possible therapeutic strategies 36
  postmenopausal 125, 137, 164
osteosarcoma cells
  effects of NO 109
  NO production 106, 107–8
ovariectomy 125, 137
oxidants 89
oxidative respiration 5
oxygen-derived free radicals
  bone resorption and 85, 86–7, 90–1
  chondrocyte apoptosis and 98
  COX-2 activation 74
  in rheumatoid bone erosions 90–3
  see also peroxynitrite; superoxide

Paget's disease 27
pannus 87–8
parallel plate flow chamber 175
parathyroid hormone (PTH) 23, 84, 117
  bone resorption and 25, 26, 84, 85
  fluid flow and 145–6
parathyroid hormone-related peptides (PTH-RP) 23, 32–3
periosteal arteries 129–30
peroxynitrite ($ONOO^-$) 5, 71, 98
  in COX-2 activation 74
  cytotoxicity 110
  loosening of hip prostheses and 180
  in rheumatoid erosions 92–3
phosphorylation, NOS isoforms 11
plasminogen activator (PA) 26, 32
plasminogen activator inhibitor (PAI) 32
plasticity, signalling 153–4, 164
platelet aggregation 12, 75
platelet-derived growth factor (PDGF) 23, 25, 85
poliomyelitis 82
polymethylacrylate particles 179, 180
posture maintenance 146
potassium perchromate (K_3CrO_8)-induced arthritis 63, 64
prednisolone 66
prolyl hydroxylase 97
prostacyclin (PGI_2) 153
  actions on bone 33
  fluid flow-induced release 157
  load-related release 152, 159–60
prostaglandin E_2
  actions on bone 33, 85
  effects of NO on production 97–8
  fluid flow-induced production 145, 157
  load-related release 152, 153, 159–60
  loosening of hip prostheses and 180
  release by osteoblasts 112
prostaglandins 25
  actions on bone 33, 86
  in experimental inflammation 72–3
  fluid flow-induced release 157, 175
  inhibition by NOS inhibitors 73, 74–5
  load-related release 152–3, 159–60, 172–3, 174
  NO interactions in inflammation 70–7
  osteoblast production 111–12
  synovial blood flow and 42–3, 45
  see also prostacyclin; prostaglandin E_2
protein kinase, cAMP-dependent 11
proteoglycans, cartilage 96–7
pseudomembrane, loosened hip prostheses 179

RA, *see* rheumatoid arthritis
rat caudal vertebrae 155–6, 170, 172
rat ulnar explants 155
reperfusion, in rheumatoid joints 87
rheumatoid arthritis (RA) 16, 41, 53
  bone erosions/synovitis 81–93
    movement and 82
    pathophysiology 84–93
    sites 81–2
    symmetry of distribution 82
    therapeutic intervention 82–4
  excessive NO production 41, 54–8, 62, 72, 98–9
  glucocorticoid therapy 66, 82
  role of NO in pathophysiology 65, 67, 119
  synovial iNOS expression 55–6, 57, 63
  typus robustus arthritis 82

sensory nerves, bone and periosteum 130
septicaemia 13–14
shear stress, fluid flow-induced 141–7, 156–7, 174
  hip prosthesis-associated 181–2
  mediating bone remodelling 143–4, 146
  sensitivity to 146
  signal transduction 145
  vs streaming potentials 144–5
sodium nitroprusside 47
space flight 134–5
c-*src* 89
Staphylococcus aureus infections 13, 14

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-17513-5 - Nitric Oxide in Bone and Joint Disease
Mika V. J. Hukkanen, Julia M. Polak and Sean P. F. Hughes
Index
More information

steroids, *see* glucocorticoids; oestrogens
'strain memory' concept 153–4, 157, 164
streaming potentials 143, 144–5, 174
streptococcal cell wall (SCW)-induced arthritis 16, 53, 63
  NOS inhibitors 64, 65–6
streptozotocin-induced diabetes 15
stretch-shear cation channels 163
stromelysin (MMP-3) 27, 32, 89
subchondral cysts 81, 82
substance P 44–5, 48, 82, 130
superantigens, bacterial 9, 10, 14
superoxide
  bone resorption and 90, 91, 180
  NO interaction 92, 98
sympathetic nerves
  bone and periosteum 130
  vasoconstriction mediated by 45–6, 47, 130–2
synovial cells, type A 55
synovial joints, *see* joints, synovial
synovial tissue
  hypoxia, in rheumatoid arthritis 87–8
  NO production, in arthritis 55–6, 63
synoviocytes, NO synthesis 42
synovitis 81
  rheumatoid, *see* rheumatoid arthritis, bone erosions/synovitis
synthesis of NO 3–4
  in cartilage 61–3, 95–6
  in osteoblasts 106, 107–10
  in synovial joints 42, 43, 61–3

T helper type 1 (T_H1) cells 12–13, 65
  in rheumatoid arthritis 88
T helper type 2 (T_H2) cells 13, 65
T lymphocytes
  loosening of hip prostheses and 179
  NO effects on activation 12–13, 65
  regulation of iNOS expression 10
  in rheumatoid arthritis 88
tetrahydrobiopterin 11
thrombin 85
thyroid hormones 85
tibia, isolated perfused rabbit 132–3, 136–07
tissue inhibitors of metalloproteinases (TIMPs) 32
TNF, *see* tumour necrosis factor
transforming growth factor β (TGFβ) 10
  actions in bone/cartilage 30–2, 85, 86, 96
  regulation of iNOS expression 11
  in rheumatoid arthritis 88
  superfamily 23, 25
transgenic animals 35
tumour necrosis factor (TNF) 28, 29
  oestrogens and 35–6
  soluble receptors (p55 and p75) 28
tumour necrosis factor α (TNFα) 9
  actions in bone/cartilage 28, 85, 86, 118
  actions on osteoblasts 108, 109
  in loosening of hip prostheses 180
  NO effects on production 13
  regulation of iNOS expression 11
  in rheumatoid arthritis 16, 88–9, 92
tumour necrosis factor β (TNFβ) 28
tumours, iNOS expression 8–9
turkey ulna model 146, 147

vascular endothelial growth factor (VEGF) 88
vascular permeability 12, 71
vasoconstriction, sympathetic-mediated 45–6, 47, 130–2
vasodilatation, NO-induced 12, 41
  in acute and chronic inflammation 71
  in bone 132–3
  in synovial joints 43–4, 47–9
venous pressure, bone formation and 134–5
venous stasis, fracture repair and 141–2
vitamin A 85

wear debris, hip prostheses 179–80, 181
weightlessness 134–5

xanthine oxidoreductase (XOR) 89, 91–2, 93

© in this web service Cambridge University Press www.cambridge.org